Chairman's Statement 2016-7
IVCC was founded with the clear and challenging mission to address the growth of insecticide resistance in vectors, by developing new insecticides for use in bednets and indoor residualspraying. The target is to develop a toolbox of compounds that could be combined or rotated to overcome resistance and prevent or delay its re-occurrence.
The Bill &Melinda Gates Foundation (BMGF) was instrumental in this, funding IVCC with an initial five-year grant of $50 million, which could be used to stimulate a process of working withprivate sector partners. This enabled the funding of a process of screening over four million leads in the chemical libraries of the major agrochemical companies and encouraging the development of public health products for what is, from a purely commercial perspective, a low priority and challenging market.
It is a tribute to the vision and co-operation of all the parties – our funders, the volunteers in the External Scientific Advisory Committees (ESACs), our industry partners, and the dedicated work of the team at IVCC— that after more than a decade we have an emerging toolbox, which potentially meets the original product specifications. Furthermore, thanks to two further major
grants from BMGF and continued support from Ukaid, USAID, Unitaid and the Swiss Agency for Development and Cooporation (SDC), as well ascritical in-kind donations of scientists, intellectual property and laboratory space access from our industrial partners, we are now set firmly on a
path towards achieving the product innovationnecessary to complete the job.
While the overall objective remains, there are many hurdles still to be cleared as well as new challenges. The first hurdle is to accelerate the registration of new products and launch them into the market. If the traditional paths of registration are followed, even given successful stop-gap re-purposing of existing products, the entry into the market will be slow and as resistance to existing products builds, there will be many unnecessary deaths from resurgent malaria.
A current priority is the cooperation being driven by the related initiative, Innovation to Impact (I2I), to bring together the relevant agencies, the WHO, the country registration bodies, and our industry partners, supported by approved test sites developed with assistance from IVCC. The aim is to achieve a more streamlined process of bringing new products to market, a goal shared by all the parties.
A second and related challenge is to keep our industry partners fully engaged with the process. Delays in bringing products to markets increases
the challenge for our industry partners to divert resources, in particular scarce skilled scientists, from more commercially pressing projects. This requires ingenuity in designing incentives and in demonstrating the advantages of continued support to our industry partners. Overcoming those challenges will deliver major progress in controlling mosquitoes which bite mainly at night and indoors using long lasting treated bednets and indoor residual spraying.
However, as disease carrying insect vectors areactive in other locations and at other times of day, we need other innovative control techniques
as well as new methods of delivery indoors.
IVCC is therefore reviewing and testing many ideas and products ranging from attractive sugar baits and repellent systems to other treated surfaces such as wall hangings. There is every reason to hope that we can continue to deliver
much needed advances in vector control and provide a vital plank in the bridge to disease elimination.
Sir Mark Moody-Stuart
A printed copy of the Annual report is available on request.